Table S3. Gene sets and patient description. ID column represents the GEO accession used to recover data; technique column describes the technique used to profile miRNAs; patients column describes information about patients, and publication describes if data were described in a publication.

ID	Technique	Patients	Publication
GSE26595	Illumina Human v2 MicroRNA expression beadchip	 - 50 primary gastric cancer tissues (27 samples: diffuse gastric cancer; 23 samples: intestinal gastric cancer). <u>Diffuse gastric cancer samples</u>: 3 stage 1b, 4 stage 2, 6 stage 3a, 6 stage 3b, 8 stage 4. <u>Intestinal gastric cancer samples</u>: 2 stage 1a, 6 stage 1b, 3 stage 2, 7 stage 3a, 2 stage 3b, 3 stage 4. - 8 surrounding non-cancer tissues 	1
GSE23739	Agilent-019118 Human miRNA Microarray 2.0 G4470B	 <u>40 gastric tumor tissue</u> <u>40 gastric normal tissue</u> 	2
GSE93415	ExiqonmiRCURYLNA microRNA array;7thgeneration(miRBase 19.0)	 20 primary tumor 20 healthy gastric mucosa	

REFERENCES

- 1. Lim, J. Y. *et al.* Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype. *World J. Gastroenterol.* (2013). doi:10.3748/wjg.v19.i41.7078
- 2. Oh, H.-K. *et al.* Genomic Loss of miR-486 Regulates Tumor Progression and the OLFM4 Antiapoptotic Factor in Gastric Cancer. *Clin. Cancer Res.* **17**, 2657–2667 (2011).